Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kuzmina, Z; Krenn, K; Petkov, V; Körmöczi, U; Weigl, R; Rottal, A; Kalhs, P; Mitterbauer, M; Ponhold, L; Dekan, G; Greinix, HT; Pickl, WF.
CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Blood. 2013; 121(10): 1886-1895.
Doi: 10.1182/blood-2012-06-435008
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Bronchiolitis obliterans syndrome (BOS), pathognomonic for chronic graft-versus-host disease (cGVHD) of the lung, is a progressive and often fatal complication after allogeneic hematopoietic cell transplantation (HCT). Biomarkers for the prediction and diagnosis of BOS are urgently needed to improve patients' prognosis. We prospectively evaluated B-cell subpopulations and B-cell activating factor (BAFF) in 136 patients (46 BOS, 41 no cGVHD, 49 cutaneous cGVHD) to define novel biomarkers for early diagnosis of National Institutes of Health-defined BOS diagnosed a median of 11 mo after HCT. Patients with newly diagnosed BOS had significantly higher percentages of CD19(+)CD21(low) B cells (25.5 versus 6.6%, P < .0001), BAFF (7.3 versus 3.5 ng/mL, P = .02), and BAFF/CD19(+) ratio (0.18 versus 0.02 ng/10(3) CD19(+) B cells, P 5 .007) compared with patients without cGVHD. The area under the receiver operating curve for CD19(+)CD21(low) B cells was 0.97 (95% confidence interval, 0.94-0.99) and a cutoff point >9% was optimal for diagnosing BOS in patients with first drop of pulmonary function tests with a sensitivity of 96% and a negative predictive value of 94%. Thus, elevated levels of CD19(+)CD21(low) B cells are a potential novel biomarker for HCT patients at risk for developing BOS at an early stage and could allow improvement of patient outcome.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antigens, CD19 - metabolism
- B-Cell Activating Factor - metabolism
- B-Lymphocytes - metabolism B-Lymphocytes - pathology
- Bronchiolitis Obliterans - diagnosis Bronchiolitis Obliterans - etiology Bronchiolitis Obliterans - metabolism Bronchiolitis Obliterans - mortality
- Chronic Disease -
- Enzyme-Linked Immunosorbent Assay -
- Female -
- Flow Cytometry -
- Graft vs Host Disease - diagnosis Graft vs Host Disease - etiology Graft vs Host Disease - metabolism Graft vs Host Disease - mortality
- Hematologic Neoplasms - complications Hematologic Neoplasms - metabolism Hematologic Neoplasms - therapy
- Hematopoietic Stem Cell Transplantation - adverse effects
- Humans -
- Immunophenotyping -
- Male -
- Middle Aged -
- National Institutes of Health (U.S.) -
- Prognosis -
- Prospective Studies -
- ROC Curve -
- Receptors, Complement 3d - metabolism
- Survival Rate -
- Transplantation, Homologous -
- Tumor Markers, Biological - metabolism
- Tumor Markers, Biological -
- Young Adult -